These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22297800)

  • 1. cGMP becomes a drug target.
    Schlossmann J; Schinner E
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Mar; 385(3):243-52. PubMed ID: 22297800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension.
    Chen CN; Watson G; Zhao L
    Vascul Pharmacol; 2013 Mar; 58(3):211-8. PubMed ID: 22982057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
    Friebe A; Sandner P; Seifert R
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1237-46. PubMed ID: 26486926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.
    Hoffmann LS; Chen HH
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Aug; 387(8):707-18. PubMed ID: 24927824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meeting report: cGMP matters.
    Kemp-Harper B; Feil R
    Sci Signal; 2008 Mar; 1(9):pe12. PubMed ID: 18319447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular variants of soluble guanylyl cyclase affecting cardiovascular risk.
    Wobst J; Rumpf PM; Dang TA; Segura-Puimedon M; Erdmann J; Schunkert H
    Circ J; 2015; 79(3):463-9. PubMed ID: 25746521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cGMP in heart failure: a new therapeutic paradigm.
    Boerrigter G; Lapp H; Burnett JC
    Handb Exp Pharmacol; 2009; (191):485-506. PubMed ID: 19089342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and regulation of soluble guanylate cyclase.
    Derbyshire ER; Marletta MA
    Annu Rev Biochem; 2012; 81():533-59. PubMed ID: 22404633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report.
    Friebe A; Kraehling JR; Russwurm M; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Aug; 396(8):1669-1686. PubMed ID: 37079081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ENaC is regulated by natriuretic peptide receptor-dependent cGMP signaling.
    Guo LJ; Alli AA; Eaton DC; Bao HF
    Am J Physiol Renal Physiol; 2013 Apr; 304(7):F930-7. PubMed ID: 23324181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic guanosine monophosphate in the regulation of the cell function.
    Zbrojkiewicz M; Śliwiński L
    Postepy Hig Med Dosw (Online); 2016 Dec; 70(0):1276-1285. PubMed ID: 28026830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of cGMP and soluble guanylyl cyclase activity.
    Southam E
    Curr Protoc Toxicol; 2001 May; Chapter 10():Unit 10.5. PubMed ID: 23045027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanylyl cyclases and signaling by cyclic GMP.
    Lucas KA; Pitari GM; Kazerounian S; Ruiz-Stewart I; Park J; Schulz S; Chepenik KP; Waldman SA
    Pharmacol Rev; 2000 Sep; 52(3):375-414. PubMed ID: 10977868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
    Kopra K; Sharina I; Martin E; Härmä H
    Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases.
    Dupont LL; Glynos C; Bracke KR; Brouckaert P; Brusselle GG
    Pulm Pharmacol Ther; 2014 Oct; 29(1):1-6. PubMed ID: 25043200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside.
    Jackson EB; Mukhopadhyay S; Tulis DA
    Curr Vasc Pharmacol; 2007 Jan; 5(1):1-14. PubMed ID: 17266609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.
    Castro LR; Schittl J; Fischmeister R
    Circ Res; 2010 Nov; 107(10):1232-40. PubMed ID: 20847310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meeting report of the 8
    Friebe A; Sandner P; Schmidtko A
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1177-1188. PubMed ID: 29018913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.